Emerging quinolone-resistant Salmonella in the United States.
We conducted a national survey of antimicrobial resistance in human clinical isolates of Salmonella between July 1, 1994, and June 30, 1995. Every tenth nontyphoidal Salmonella isolate received at state public health laboratories in the United States during this period was tested for resistance to 12 antimicrobial agents, including two quinolones, nalidixic acid, and ciprofloxacin. Emerging quinolone resistance was detected; of 4,008 isolates tested, 21 (0.5%) were resistant to nalidixic acid, and one (0.02%) was resistant to ciprofloxacin. Continued surveillance for quinolone-resistant Salmonella is necessary, particularly after the recent approval of a fluoroquinolone for use in animals intended for food in the United States.
Herikstad
H
H
Centers for Disease Control and Prevention, Atlanta, Gerogia, USA.
Hayes
P
P
Mokhtar
M
M
Fracaro
M L
ML
Threlfall
E J
EJ
Angulo
F J
FJ
D000821:Animal Feed; D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D006801:Humans; D009268:Nalidixic Acid / Q000494:pharmacology; D012475:Salmonella / Q000187:drug effects* / Q000302:isolation & purification*; D012480:Salmonella Infections / Q000188:drug therapy / Q000382:microbiology; D014481:United States
D000890:Anti-Infective Agents; D009268:Nalidixic Acid; D002939:Ciprofloxacin